Please provide your email address to receive an email when new articles are posted on . The interleukin-5 inhibitor benralizumab yielded durable remission rates in EGPA. The drug showed no new safety ...
Benralizumab injections reduce exacerbations in severe, uncontrolled asthma, according to two trials
A year's course of benralizumab injections has led to a significant decrease in the frequency of asthma exacerbations -- cutting the rate of exacerbations by a third to a half compared with placebo ...
While treatment with benralizumab showed numerical improvement over placebo for the primary endpoint, the result was not statistically significant. A phase 3 trial evaluating benralizumab for the ...
Please provide your email address to receive an email when new articles are posted on . This patient population had “better outcomes” when receiving benralizumab with or without prednisolone vs.
Benralizumab, an interleukin-5 (IL-5) antagonist used to treat severe asthma, does not weaken antibody response of influenza vaccinations, according to results of a recent study. Benralizumab, an ...
The approval of benralizumab (Fasenra) is supported by evidence from the phase 3 TATE study. The FDA has approved benralizumab (Fasenra) for children aged 6 to 11 years with severe eosinophilic asthma ...
Eosinophil White Blood Cell What is the difference in efficacy between mepolizumab and benralizumab, 2 biologics approved for the treatment of severe eosinophilic asthma? Mepolizumab and benralizumab ...
Benralizumab, an anti–interleukin-5 receptor alpha monoclonal antibody, was significantly better than placebo at producing a histologic response of up to six eosinophils per high-power field (eos/hpf) ...
The evaluation committee considered evidence submitted by AstraZeneca, a review of this submission by the external assessment group (EAG), and responses from stakeholders. See the committee papers for ...
Learn everything you need to know about Benralizumab-pronunciation, uses, dosage guidelines, indications, and when to take or avoid it. Get up-to-date information on side effects, precautions, ...
The appraisal committee considered evidence submitted by AstraZeneca and a review of this submission by the evidence review group (ERG). See the committee papers for full details of the evidence.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results